Cargando…

Percutaneous cryoablation: a novel treatment option in non-visceral metastases of the abdominal cavity after prior surgery

PURPOSE: To assess the primary safety and oncological outcome of percutaneous cryoablation in patients with non-visceral metastases of the abdominal cavity after prior surgery. METHODS: All patients with non-visceral metastases after prior abdominal surgery, treated with percutaneous cryoablation, a...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Reijd, D. J., Baetens, T. R., Gomez Munoz, F., Aarts, B. M., Lahaye, M. J., Graafland, N. M., Lok, C. A. R., Aalbers, A. G. J., Kok, N. F. M., Beets-Tan, R. G. H., Maas, M., Klompenhouwer, E. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388473/
https://www.ncbi.nlm.nih.gov/pubmed/35779093
http://dx.doi.org/10.1007/s00261-022-03598-y
_version_ 1784770233388498944
author van der Reijd, D. J.
Baetens, T. R.
Gomez Munoz, F.
Aarts, B. M.
Lahaye, M. J.
Graafland, N. M.
Lok, C. A. R.
Aalbers, A. G. J.
Kok, N. F. M.
Beets-Tan, R. G. H.
Maas, M.
Klompenhouwer, E. G.
author_facet van der Reijd, D. J.
Baetens, T. R.
Gomez Munoz, F.
Aarts, B. M.
Lahaye, M. J.
Graafland, N. M.
Lok, C. A. R.
Aalbers, A. G. J.
Kok, N. F. M.
Beets-Tan, R. G. H.
Maas, M.
Klompenhouwer, E. G.
author_sort van der Reijd, D. J.
collection PubMed
description PURPOSE: To assess the primary safety and oncological outcome of percutaneous cryoablation in patients with non-visceral metastases of the abdominal cavity after prior surgery. METHODS: All patients with non-visceral metastases after prior abdominal surgery, treated with percutaneous cryoablation, and at least one year of follow-up were retrospectively identified. Technical success was achieved if the ice-ball had a minimum margin of 10 mm in three dimensions on the per-procedural CT images. Complications were recorded using the Society of Interventional Radiology (SIR) classification system. Time until disease progression was monitored with follow-up CT and/or MRI. Local control was defined as absence of recurrence at the site of ablation. RESULTS: Eleven patients underwent cryoablation for 14 non-visceral metastases (mean diameter 20 ± 9 mm). Primary tumor origin was renal cell (n = 4), colorectal (n = 3), granulosa cell (n = 2), endometrium (n = 1) and appendix (n = 1) carcinoma. Treated metastases were localized retroperitoneal (n = 8), intraperitoneal (n = 2), or in the abdominal wall (n = 4). Technical success was achieved in all procedures. After a median follow-up of 27 months (12–38 months), all patients were alive. Local control was observed in 10/14 non-visceral metastases, and the earliest local progression was detected after ten months. No major adverse events occurred. One patient suffered a minor asymptomatic adverse event. CONCLUSION: This proof-of-concept study suggests that cryoablation can be a minimal invasive treatment option in a selected group of patients with non-visceral metastases in the abdominal cavity after prior surgery. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-9388473
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-93884732022-08-20 Percutaneous cryoablation: a novel treatment option in non-visceral metastases of the abdominal cavity after prior surgery van der Reijd, D. J. Baetens, T. R. Gomez Munoz, F. Aarts, B. M. Lahaye, M. J. Graafland, N. M. Lok, C. A. R. Aalbers, A. G. J. Kok, N. F. M. Beets-Tan, R. G. H. Maas, M. Klompenhouwer, E. G. Abdom Radiol (NY) Interventional Radiology PURPOSE: To assess the primary safety and oncological outcome of percutaneous cryoablation in patients with non-visceral metastases of the abdominal cavity after prior surgery. METHODS: All patients with non-visceral metastases after prior abdominal surgery, treated with percutaneous cryoablation, and at least one year of follow-up were retrospectively identified. Technical success was achieved if the ice-ball had a minimum margin of 10 mm in three dimensions on the per-procedural CT images. Complications were recorded using the Society of Interventional Radiology (SIR) classification system. Time until disease progression was monitored with follow-up CT and/or MRI. Local control was defined as absence of recurrence at the site of ablation. RESULTS: Eleven patients underwent cryoablation for 14 non-visceral metastases (mean diameter 20 ± 9 mm). Primary tumor origin was renal cell (n = 4), colorectal (n = 3), granulosa cell (n = 2), endometrium (n = 1) and appendix (n = 1) carcinoma. Treated metastases were localized retroperitoneal (n = 8), intraperitoneal (n = 2), or in the abdominal wall (n = 4). Technical success was achieved in all procedures. After a median follow-up of 27 months (12–38 months), all patients were alive. Local control was observed in 10/14 non-visceral metastases, and the earliest local progression was detected after ten months. No major adverse events occurred. One patient suffered a minor asymptomatic adverse event. CONCLUSION: This proof-of-concept study suggests that cryoablation can be a minimal invasive treatment option in a selected group of patients with non-visceral metastases in the abdominal cavity after prior surgery. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2022-07-02 2022 /pmc/articles/PMC9388473/ /pubmed/35779093 http://dx.doi.org/10.1007/s00261-022-03598-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Interventional Radiology
van der Reijd, D. J.
Baetens, T. R.
Gomez Munoz, F.
Aarts, B. M.
Lahaye, M. J.
Graafland, N. M.
Lok, C. A. R.
Aalbers, A. G. J.
Kok, N. F. M.
Beets-Tan, R. G. H.
Maas, M.
Klompenhouwer, E. G.
Percutaneous cryoablation: a novel treatment option in non-visceral metastases of the abdominal cavity after prior surgery
title Percutaneous cryoablation: a novel treatment option in non-visceral metastases of the abdominal cavity after prior surgery
title_full Percutaneous cryoablation: a novel treatment option in non-visceral metastases of the abdominal cavity after prior surgery
title_fullStr Percutaneous cryoablation: a novel treatment option in non-visceral metastases of the abdominal cavity after prior surgery
title_full_unstemmed Percutaneous cryoablation: a novel treatment option in non-visceral metastases of the abdominal cavity after prior surgery
title_short Percutaneous cryoablation: a novel treatment option in non-visceral metastases of the abdominal cavity after prior surgery
title_sort percutaneous cryoablation: a novel treatment option in non-visceral metastases of the abdominal cavity after prior surgery
topic Interventional Radiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388473/
https://www.ncbi.nlm.nih.gov/pubmed/35779093
http://dx.doi.org/10.1007/s00261-022-03598-y
work_keys_str_mv AT vanderreijddj percutaneouscryoablationanoveltreatmentoptioninnonvisceralmetastasesoftheabdominalcavityafterpriorsurgery
AT baetenstr percutaneouscryoablationanoveltreatmentoptioninnonvisceralmetastasesoftheabdominalcavityafterpriorsurgery
AT gomezmunozf percutaneouscryoablationanoveltreatmentoptioninnonvisceralmetastasesoftheabdominalcavityafterpriorsurgery
AT aartsbm percutaneouscryoablationanoveltreatmentoptioninnonvisceralmetastasesoftheabdominalcavityafterpriorsurgery
AT lahayemj percutaneouscryoablationanoveltreatmentoptioninnonvisceralmetastasesoftheabdominalcavityafterpriorsurgery
AT graaflandnm percutaneouscryoablationanoveltreatmentoptioninnonvisceralmetastasesoftheabdominalcavityafterpriorsurgery
AT lokcar percutaneouscryoablationanoveltreatmentoptioninnonvisceralmetastasesoftheabdominalcavityafterpriorsurgery
AT aalbersagj percutaneouscryoablationanoveltreatmentoptioninnonvisceralmetastasesoftheabdominalcavityafterpriorsurgery
AT koknfm percutaneouscryoablationanoveltreatmentoptioninnonvisceralmetastasesoftheabdominalcavityafterpriorsurgery
AT beetstanrgh percutaneouscryoablationanoveltreatmentoptioninnonvisceralmetastasesoftheabdominalcavityafterpriorsurgery
AT maasm percutaneouscryoablationanoveltreatmentoptioninnonvisceralmetastasesoftheabdominalcavityafterpriorsurgery
AT klompenhouwereg percutaneouscryoablationanoveltreatmentoptioninnonvisceralmetastasesoftheabdominalcavityafterpriorsurgery